DGX
QUEST DIAGNOSTICS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 21 ▲ Quest Diagnostics reported strong Q1 2026 results with revenue of $2…
- Jun 1 to Jun 4 ▼ 2 days of insider sells: $3.6M by 2 insiders, avg $196.77
- Jun 22 Lawanda House Johnson v. Quest Diagnostics Inc
- Jul 28 ▼ 1 insider sell $376.3K at $235.18
- Aug 28 to Sep 1 ▼ 2 days of insider sells: $7.9M by 2 insiders, avg $242.99
- Sep 4 ▲ Ro Khanna bought $1,001 - $15,000, last disclosed Oct 9
- Sep 9 ▲ Quest Diagnostics reported Q2 2026 EPS of $3.12, a 9.0% beat vs the…
- Oct 7 ▼ Ro Khanna sold $1,001 - $15,000, last disclosed Nov 9
- Oct 22 ▲ Quest Diagnostics reported Q3 2026 revenue of $3.097B (+10.0% YoY) a…
- Oct 26 ▼ 1 insider sell $292.3K at $243.00
- Nov 3 to Nov 9 ▼ 2 days of insider sells: $8.5M by 2 insiders, avg $251.25
- Nov 10 Dividend: Quest Diagnostics Declares Quarterly Cash Dividend
Signal stack
Where each data set points today.
- InsidersBEARISH
7 insiders sold $20.7M.
- InstitutionsBULLISH
Q2 2026: 44 added (2 new), 24 trimmed or exited. Largest new: Pfa Pension, Forsikringsaktieselskab $43.6M, Adage Capital Partners Gp, L.L.C $22.5M.
- AnalystsBULLISH
12 of 23 rate it Buy or better. Median target $260.00 (−1%).
- Short sellersSTEADY
Short interest +4.5% to 3.73M shares. 3.6 days to cover, ≈3.4% of shares.
- TrendUPTREND
8% above its 50-day average. New closing high $261.70 on Nov 16.
- SocialQUIET
Crowd 60° (warm) this week from 6 mentions: 2 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $296.5M |
| GOLDMAN SACHS GROUP INC | TRIM | $208.3M |
| UBS Group AG | ADD | $188.4M |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | $88.8M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $83.8M |
| Qube Research & Technologies Ltd | TRIM | $72.8M |
| MACKENZIE FINANCIAL CORP | DOUBLED | $70.6M |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | $58.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
23 analystsPrice is inside the target range. Median implies −1%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 7, 2026 | Barclays MAINTAIN | Overweight |
| Sep 21, 2026 | Truist Securities MAINTAIN | Hold |
| Sep 8, 2026 | UBS MAINTAIN | Neutral |
| Jul 28, 2026 | JP Morgan MAINTAIN | Neutral |
| Jul 24, 2026 | UBS MAINTAIN | Neutral |
| Jul 24, 2026 | Mizuho MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Plewman Patrick SVP for Diagnostic Services Nov 9, 2026 | EXERCISE | $545.9K |
Plewman Patrick SVP for Diagnostic Services Nov 9, 2026 | SELL | $1.1M |
Plewman Patrick SVP for Diagnostic Services Nov 9, 2026 | SELL | $1.7M |
Plewman Patrick SVP for Diagnostic Services Nov 9, 2026 | SELL | $167.3K |
Plewman Patrick SVP for Diagnostic Services Nov 9, 2026 | EXERCISE | $868.2K |
DELANEY MARK E SVP & Chief Commercial Officer Nov 3, 2026 | AWARD | 2,615 sh |
Doherty Catherine T. Executive Vice President Nov 3, 2026 | AWARD | 4,827 sh |
Doherty Catherine T. Executive Vice President Nov 3, 2026 | EXERCISE | $2.7M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026Washington
SecBot reports
22 filings · 1 press release · 4 bullish · 1 bearish · 1 mixed · 16 neutral- NEUTRAL CLUSTERNov 12, 2026
Two DGX insiders (SVP Plewman and EVP Doherty) sold a combined $2.57M in open-market sales, both…
Sales are small and pre-planned under 10b5-1 programs. No read-through to fundamentals. Monitor next quarterly filing for any operational changes.
- NEUTRAL PRESS RELEASENov 10, 2026
Quest Diagnostics declared a quarterly cash dividend of $0.86 per share, payable on January 27…
Dividend unchanged from prior quarter; no signal of a change in capital return policy. Monitor next earnings release for any update on buyback or dividend growth plans.
- NEUTRAL SC 13GNov 10, 2026
State Street Corp disclosed a passive 5.0% stake in Quest Diagnostics as of September 30, 2026…
State Street's passive 5% stake adds to the existing Vanguard Group holdings. Monitor for any future 13D conversion or additional accumulation, though the 13G certification indicates no activist…
- NEUTRAL PRESS-RELEASENov 9, 2026
Quest Diagnostics announced CFO Sam Samad will participate in a fireside chat at a healthcare…
Monitor the webcast for any strategic commentary or business updates, though no material disclosures are expected from a routine conference appearance.
All DGX filing & press-release reports (23)
- CLUSTER reportNov 12, 2026
- PRESS-RELEASE reportNov 10, 2026
- SC 13G reportNov 10, 2026
- PRESS-RELEASE reportNov 9, 2026
- 144 reportNov 9, 2026
- 3 reportNov 5, 2026
- INST-CLUSTER reportNov 3, 2026
- 144 reportNov 3, 2026
- INST-CLUSTER reportOct 27, 2026
- 144 reportOct 26, 2026
- 8-K reportOct 22, 2026
- 8-K reportOct 22, 2026
- 8-K reportOct 6, 2026
- PRESS-RELEASE reportSep 22, 2026
- PRESS-RELEASE reportSep 9, 2026
- CLUSTER reportSep 3, 2026
- 8-K reportJul 23, 2026
- COURT-RULING reportApr 16, 2026
- 8-K reportMay 8, 2026
- 8-K reportApr 21, 2026
- CLUSTER reportMar 5, 2026
- CLUSTER reportMar 3, 2026
- CLUSTER reportMar 3, 2026